Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 244

1.

Thimerosal exposure in infants and neurodevelopmental disorders: an assessment of computerized medical records in the Vaccine Safety Datalink.

Young HA, Geier DA, Geier MR.

J Neurol Sci. 2008 Aug 15;271(1-2):110-8. doi: 10.1016/j.jns.2008.04.002. Epub 2008 May 15.

PMID:
18482737
2.

Thimerosal exposure & increasing trends of premature puberty in the vaccine safety datalink.

Geier DA, Young HA, Geier MR.

Indian J Med Res. 2010 Apr;131:500-7.

3.

Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases.

Verstraeten T, Davis RL, DeStefano F, Lieu TA, Rhodes PH, Black SB, Shinefield H, Chen RT; Vaccine Safety Datalink Team.

Pediatrics. 2003 Nov;112(5):1039-48. Erratum in: Pediatrics. 2004 Jan;113(1):184.

PMID:
14595043
4.

A two-phased population epidemiological study of the safety of thimerosal-containing vaccines: a follow-up analysis.

Geier DA, Geier MR.

Med Sci Monit. 2005 Apr;11(4):CR160-70. Epub 2005 Mar 24.

PMID:
15795695
5.
6.

Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association.

Andrews N, Miller E, Grant A, Stowe J, Osborne V, Taylor B.

Pediatrics. 2004 Sep;114(3):584-91.

PMID:
15342825
7.

A dose-response relationship between organic mercury exposure from thimerosal-containing vaccines and neurodevelopmental disorders.

Geier DA, Hooker BS, Kern JK, King PG, Sykes LK, Geier MR.

Int J Environ Res Public Health. 2014 Sep 5;11(9):9156-70. doi: 10.3390/ijerph110909156.

8.
10.

Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations.

Fombonne E, Zakarian R, Bennett A, Meng L, McLean-Heywood D.

Pediatrics. 2006 Jul;118(1):e139-50.

PMID:
16818529
12.

Regression of language and non-language skills in pervasive developmental disorders.

Meilleur AA, Fombonne E.

J Intellect Disabil Res. 2009 Feb;53(2):115-24. doi: 10.1111/j.1365-2788.2008.01134.x. Epub 2008 Nov 27.

PMID:
19054269
13.
14.

Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years.

Thompson WW, Price C, Goodson B, Shay DK, Benson P, Hinrichsen VL, Lewis E, Eriksen E, Ray P, Marcy SM, Dunn J, Jackson LA, Lieu TA, Black S, Stewart G, Weintraub ES, Davis RL, DeStefano F; Vaccine Safety Datalink Team.

N Engl J Med. 2007 Sep 27;357(13):1281-92.

15.
16.

Neurodevelopmental disorders after thimerosal-containing vaccines: a brief communication.

Geier MR, Geier DA.

Exp Biol Med (Maywood). 2003 Jun;228(6):660-4.

PMID:
12773696
17.

Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data.

Parker SK, Schwartz B, Todd J, Pickering LK.

Pediatrics. 2004 Sep;114(3):793-804. Review. Erratum in: Pediatrics. 2005 Jan;115(1):200.

PMID:
15342856
18.

Neurodevelopmental disorders, maternal Rh-negativity, and Rho(D) immune globulins: a multi-center assessment.

Geier DA, Mumper E, Gladfelter B, Coleman L, Geier MR.

Neuro Endocrinol Lett. 2008 Apr;29(2):272-80.

PMID:
18404135
19.
20.

An assessment of the impact of thimerosal on childhood neurodevelopmental disorders.

Geier DA, Geier MR.

Pediatr Rehabil. 2003 Apr-Jun;6(2):97-102.

PMID:
14534046

Supplemental Content

Support Center